查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951781

藥物研發服務市場分析及預測（至2035年）：依類型、產品類型、服務、技術、組件、應用、流程、部署類型及最終用戶分類

Drug Discovery Services Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Process, Deployment, End User
出版日期: | 出版商: Global Insight Services | 英文 393 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，藥物研發服務市場規模將從2024年的191億美元成長至602億美元，複合年成長率約為12.7%。藥物研發服務市場涵蓋外包研發服務，旨在協助製藥公司識別和開發新藥。這些服務包括標靶分子識別、先導化合物最佳化和臨床前試驗。市場成長的促進因素包括研發投入的增加、藥物研發過程日益複雜以及對具成本效益解決方案的需求。人工智慧和機器學習等技術進步正在提升服務效率，而策略合作和協同研究則推動了服務組合的擴展。慢性病盛行率的上升以及對新型治療方法日益成長的需求也是推動市場成長的重要因素。

受創新藥物解決方案需求不斷成長的推動，藥物研發服務市場正經歷強勁成長。先導化合物鑑定和候選化合物最佳化細分市場成長最為顯著，這主要得益於篩檢技術和計算方法的進步。此細分市場對於識別潛在候選藥物並對其進行最佳化以用於治療應用至關重要。藥物化學服務細分市場也緊隨其後，反映出市場對化合物合成和最佳化方面專業知識的需求日益成長。該領域對於開發療效和安全性更高的新藥至關重要。此外，體外服務領域也發展迅猛，尤其是在基於細胞的檢測和高通量篩檢方面，這些在藥物研發的早期階段至關重要。市場對生物製劑和小分子藥物的需求也在激增，日益重視個人化醫療。這一趨勢凸顯了藥物研發中個人化方法的重要性，它能夠提高治療的精準性和有效性。

市場區隔
類型 高通量篩檢、生物資訊學、藥物基因體學、組合化學、奈米技術
產品 檢測方法開發、先導化合物發現、先導化合物最佳化、標靶檢驗
服務 生物物理特性、生化篩檢、ADME-Tox 測試
科技 基於細胞的檢測、In Silico模擬和高內涵篩檢
成分 軟體、硬體和試劑
應用領域 腫瘤學、神經病學、心血管疾病、感染疾病、免疫學
過程 目標選擇，從命中到線索，從線索到候選人
實施表格 本機部署、雲端部署
最終用戶 製藥公司、生技公司、學術機構、合約研究組織

藥物研發服務市場以服務多樣化為特徵，市佔率分散在幾家主要企業之間。定價策略競爭激烈，反映了該行業對創新和具成本效益解決方案的需求。近期推出的產品凸顯了個人化醫療和先進治療方法的發展趨勢。各公司日益重視策略夥伴關係，以增強其服務組合併擴大地域覆蓋範圍。藥物研發服務市場的競爭異常激烈，許多公司競相透過技術創新和服務差異化來主導。監管因素，尤其是在北美和歐洲，對市場動態的塑造起著至關重要的作用。這些法規確保了品質和安全，並對服務內容和商業策略產生影響。在有利的政府政策和快速發展的製藥業的推動下，亞太地區的新興市場正在吸引越來越多的投資。人工智慧和機器學習的進步進一步豐富了市場格局，為成長和效率提升開闢了新的途徑。

主要趨勢和促進因素：

藥物研發服務市場正經歷強勁成長，這主要得益於幾個關鍵趨勢和促進因素。對個人化醫療的日益重視正推動製藥公司採用更專業的藥物研發流程。基因組學和生物技術的進步為這一轉變提供了夥伴關係充分發揮了雙方的優勢，促進了創新並加速了藥物研發進程。此外，慢性病的快速成長以及對新型療法的迫切需求也推動了市場擴張。政府和私營機構對研發的大量投入進一步促進了市場成長。將藥物研發服務外包給專業公司也是推動市場成長的重要因素。這一趨勢主要源自於服務供應商提供的成本效益和專業知識，使製藥公司能夠專注於自身的核心競爭力。在監管環境日益嚴格的背景下，對全面合規的藥物研發服務的需求也在不斷成長，為市場參與者提供了盈利的機會。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 高通量篩檢
    • 生物資訊學
    • 藥物基因體學
    • 組合化學
    • 奈米科技
  • 市場規模及預測：依產品分類
    • 檢測方法開發
    • 先導化合物鑑定
    • 先導藥物最適化
    • 目標檢驗
  • 市場規模及預測：依服務分類
    • 生物物理特性
    • 生化篩檢
    • ADME-毒理學研究
  • 市場規模及預測：依技術分類
    • 基於細胞的檢測
    • In Silico模擬
    • 高內涵篩檢
  • 市場規模及預測：依組件分類
    • 軟體
    • 硬體
    • 試劑
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 神經病學
    • 心血管疾病
    • 感染疾病
    • 免疫學
  • 市場規模及預測：依製程分類
    • 目標選擇
    • 從先導化合物衍生先導化合物
    • 從先導化合物到候選化合物
  • 市場規模及預測：依發展狀況
    • 本地部署
    • 基於雲端的
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 學術機構
    • 合約研究機構

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Charles River Laboratories
  • Wu Xi App Tec
  • Eurofins Scientific
  • Evotec
  • Syngene International
  • Pharmaron
  • Gen Script Biotech
  • Medpace
  • ICON plc
  • Covance
  • PRA Health Sciences
  • Frontage Laboratories
  • Chem Partner
  • Quotient Sciences
  • Selvita
  • Bio Duro
  • Crown Bioscience
  • Tecan Group
  • Envigo
  • Reaction Biology Corporation

第9章：關於我們

簡介目錄
Product Code: GIS20713

Drug Discovery Services Market is anticipated to expand from $19.1 billion in 2024 to $60.2 billion by 2034, growing at a CAGR of approximately 12.7%. The Drug Discovery Services Market encompasses outsourced research and development services aiding pharmaceutical companies in identifying and developing new drugs. It includes target identification, lead optimization, and preclinical testing. This market is driven by increasing R&D investments, the complexity of drug discovery, and the need for cost-effective solutions. Technological advancements, such as AI and machine learning, are enhancing service efficiency, while strategic partnerships and collaborations are expanding service portfolios. The market's growth is propelled by the rising prevalence of chronic diseases and the demand for novel therapeutics.

The Drug Discovery Services Market is experiencing robust growth, propelled by the increasing demand for innovative pharmaceutical solutions. The lead identification and candidate optimization sub-segment stands out as the top-performing area, driven by advancements in screening technologies and computational methods. This sub-segment is crucial for identifying potential drug candidates and refining them for therapeutic use. The medicinal chemistry services sub-segment follows closely, reflecting the growing need for expertise in synthesizing and optimizing chemical compounds. This area is vital for developing new drugs with improved efficacy and safety profiles. Furthermore, the in-vitro services segment is gaining momentum, particularly in the realms of cell-based assays and high-throughput screening, which are instrumental in early-stage drug discovery. The market is also witnessing a surge in demand for biologics and small molecules, with an emphasis on personalized medicine. This trend underscores the importance of tailored approaches in drug development, enhancing the precision and effectiveness of treatments.

Market Segmentation
TypeHigh Throughput Screening, Bioinformatics, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology
ProductAssay Development, Lead Identification, Lead Optimization, Target Validation
ServicesBiophysical Characterization, Biochemical Screening, ADME-Tox Testing
TechnologyCell-based Assays, In Silico Modeling, High Content Screening
ComponentSoftware, Hardware, Reagents
ApplicationOncology, Neurology, Cardiovascular Diseases, Infectious Diseases, Immunology
ProcessTarget Selection, Hit-to-Lead, Lead-to-Candidate
DeploymentOn-premise, Cloud-based
End UserPharmaceutical Companies, Biotechnology Companies, Academic Institutions, Contract Research Organizations

The Drug Discovery Services Market is characterized by a diverse array of offerings, with market share distributed among several key players. Pricing strategies are competitive, reflecting the innovative nature of the sector and the demand for cost-effective solutions. Recent product launches underscore a trend towards personalized medicine and advanced therapeutic modalities. Companies are increasingly focusing on strategic partnerships and collaborations to enhance their service portfolios and expand their geographical reach. Competition in the Drug Discovery Services Market is intense, with numerous players vying for leadership through technological innovation and service differentiation. Regulatory influences, particularly in North America and Europe, play a pivotal role in shaping market dynamics. These regulations ensure quality and safety, impacting service delivery and operational strategies. Emerging markets in Asia-Pacific are witnessing increased investments, driven by favorable government policies and a burgeoning pharmaceutical sector. The market landscape is further enriched by advancements in AI and machine learning, offering new avenues for growth and efficiency.

Geographical Overview:

The Drug Discovery Services Market is expanding across various regions, each characterized by unique growth dynamics. North America remains at the forefront, propelled by robust research and development investments and a strong presence of pharmaceutical giants. The region's emphasis on innovative drug discovery techniques catalyzes further market expansion. Europe follows with a focus on personalized medicine and collaborative research initiatives, enhancing its market position. Asia Pacific is witnessing rapid growth, driven by an increasing number of contract research organizations and government support for pharmaceutical research. Emerging economies like China and India are pivotal growth pockets, offering cost-effective services and a skilled workforce. Latin America and the Middle East & Africa are nascent markets with growing potential. In Latin America, rising healthcare expenditures and an expanding pharmaceutical sector fuel demand for drug discovery services. Meanwhile, the Middle East & Africa are increasingly investing in healthcare infrastructure, recognizing the market's potential to drive innovation and economic development.

The Drug Discovery Services Market is navigating a complex landscape shaped by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, companies are enhancing domestic capabilities to mitigate risks from US-China trade tensions, investing in cutting-edge technologies and strategic partnerships. China's focus on self-sufficiency is accelerating its investment in innovative drug discovery platforms, while Taiwan leverages its advanced biotech expertise amid geopolitical uncertainties. The global parent market remains robust, driven by technological advancements and increased R&D investments. By 2035, the market is projected to flourish through strategic regional collaborations and resilient supply chains. Middle East conflicts, influencing energy prices, could indirectly impact operational costs and timelines, necessitating adaptive strategies in energy management and logistics.

Key Trends and Drivers:

The drug discovery services market is experiencing robust growth due to several pivotal trends and drivers. An increasing emphasis on personalized medicine is steering pharmaceutical companies towards more specialized drug discovery processes. This shift is supported by advancements in genomics and biotechnology, which enable the development of tailored therapeutic solutions. Additionally, the rise of artificial intelligence and machine learning is revolutionizing the drug discovery landscape by enhancing the efficiency and accuracy of identifying potential drug candidates. Another significant trend is the growing collaboration between academic institutions and pharmaceutical companies. This partnership fosters innovation and accelerates the drug discovery process, leveraging the strengths of both sectors. Moreover, the surge in chronic diseases and the urgent need for novel therapeutics are propelling market expansion. Governments and private entities are investing heavily in research and development, further fueling growth. The increasing outsourcing of drug discovery services to specialized firms is another key driver. This trend is largely due to the cost-efficiency and expertise offered by service providers, enabling pharmaceutical companies to focus on their core competencies. As the regulatory landscape becomes more stringent, the demand for comprehensive and compliant drug discovery services is also on the rise, presenting lucrative opportunities for market players.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by End User

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 High Throughput Screening
    • 4.1.2 Bioinformatics
    • 4.1.3 Pharmacogenomics
    • 4.1.4 Combinatorial Chemistry
    • 4.1.5 Nanotechnology
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Assay Development
    • 4.2.2 Lead Identification
    • 4.2.3 Lead Optimization
    • 4.2.4 Target Validation
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Biophysical Characterization
    • 4.3.2 Biochemical Screening
    • 4.3.3 ADME-Tox Testing
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cell-based Assays
    • 4.4.2 In Silico Modeling
    • 4.4.3 High Content Screening
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Software
    • 4.5.2 Hardware
    • 4.5.3 Reagents
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Oncology
    • 4.6.2 Neurology
    • 4.6.3 Cardiovascular Diseases
    • 4.6.4 Infectious Diseases
    • 4.6.5 Immunology
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Target Selection
    • 4.7.2 Hit-to-Lead
    • 4.7.3 Lead-to-Candidate
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 On-premise
    • 4.8.2 Cloud-based
  • 4.9 Market Size & Forecast by End User (2020-2035)
    • 4.9.1 Pharmaceutical Companies
    • 4.9.2 Biotechnology Companies
    • 4.9.3 Academic Institutions
    • 4.9.4 Contract Research Organizations

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 End User
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 End User
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 End User
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 End User
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 End User
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 End User
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 End User
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 End User
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 End User
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 End User
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 End User
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 End User
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 End User
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 End User
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 End User
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 End User
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 End User
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 End User
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 End User
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 End User
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 End User
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 End User
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 End User
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 End User

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Charles River Laboratories
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Wu Xi App Tec
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Eurofins Scientific
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Evotec
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Syngene International
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Pharmaron
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Gen Script Biotech
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Medpace
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 ICON plc
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Covance
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 PRA Health Sciences
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Frontage Laboratories
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Chem Partner
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Quotient Sciences
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Selvita
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Bio Duro
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Crown Bioscience
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Tecan Group
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Envigo
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Reaction Biology Corporation
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us